Background Severe early-onset fetal growth restriction (FGR) predisposes to fetal death,
neonatal death, neonatal morbidity and neurodisability. The use of placental biomarkers has
been proposed for risk stratification in pre-eclampsia, but they could be equally useful in
fetal growth restriction in aiding management. Objective To determine the efficacy of
angiogenic biomarkers at predicting adverse pregnancy outcome in severe early-onset fetal
growth restriction. Study design This is a secondary analysis of the multicentre, placebo …